Infliximab enhances intestinal regeneration and residual function following rescue therapy for acute cellular rejection (ACR) after rat small bowel transplantation

Thomas Pech, Ichiro Ohsawa, Michael Praktiknjo, Tobias Finger, Kareem Abu-Elmagd, Andreas Hirner, Jörg C. Kalff, Andreas Türler & Nico Schäfer
Introduction: The small intestine is highly immunogenic and there is rising evidence that recurrent ACR episodes may trigger chronic rejection, having influence on the long term outcome. In previous studies, we established an experimental model to analyze the recovery and regeneration process after [for full text, please go to the a.m. URL]